These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27347650)

  • 1. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
    Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR
    HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
    Salata RA; Grinsztejn B; Ritz J; Collier AC; Hogg E; Gross R; Godfrey C; Kumarasamy N; Kanyama C; Mellors JW; Wallis CL; Hughes MD;
    AIDS Res Ther; 2023 Jan; 20(1):3. PubMed ID: 36604746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
    Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
    Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.
    Gordon LL; Gharibian D; Chong K; Chun H
    AIDS Patient Care STDS; 2015 Jul; 29(7):384-8. PubMed ID: 26114665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
    Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
    BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term virological outcome in children receiving first-line antiretroviral therapy.
    Chandrasekaran P; Shet A; Srinivasan R; Sanjeeva GN; Subramanyan S; Sunderesan S; Ramesh K; Gopalan B; Suresh E; Poornagangadevi N; Hanna LE; Chandrasekar C; Wanke C; Swaminathan S
    AIDS Res Ther; 2018 Nov; 15(1):23. PubMed ID: 30477526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.
    Marconi VC; Wu B; Hampton J; Ordóñez CE; Johnson BA; Singh D; John S; Gordon M; Hare A; Murphy R; Nachega J; Kuritzkes DR; del Rio C; Sunpath H;
    AIDS Patient Care STDS; 2013 Dec; 27(12):657-68. PubMed ID: 24320011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after virologic failure of first-line ART in South Africa.
    Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
    AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.
    Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y
    BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Kozal MJ; Hullsiek KH; Miller MD; Bangsberg DR; Kuritzkes DR
    AIDS; 2012 Jan; 26(2):185-92. PubMed ID: 22179227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment.
    Chohan BH; Ronen K; Khasimwa B; Matemo D; Osborn L; Unger JA; Drake AL; Beck IA; Frenkel LM; Kinuthia J; John-Stewart G
    PLoS One; 2021; 16(8):e0256249. PubMed ID: 34407133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China.
    Yan J; Liu J; Su B; Pan X; Wang Z; Wu J; Zhang J; Ruan Y; Hsi J; Liao L; Shao Y; Xing H
    PLoS One; 2016; 11(4):e0154421. PubMed ID: 27119346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.